Generate Biomedicines

GENB

14.4608.31% ( -1.310 )

Closed: Oct 30, 16:00:00 (EDT)

Q2 FY2026 EarningsQ2 FY26 results beat consensus on the top and bottom lines: revenue was $6.3M vs. $5.3M expected, and GAAP EPS was -$0.52 vs. -$0.53 expected. Collaboration revenue, while down 38% YoY, exceeded estimates due to milestones in the Amgen and Novartis programs. The net loss of $67.3M was slightly narrower than the $67.9M consensus, supported by a healthy cash position of $457.4M which extends the runway into H1 2028.

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Generate Biomedicines(GENB) the Revenue is 6.314 M (--%), Beat estimate;the EBIT is -71.61 M (--%), Miss estimate;the EPS is -0.52 (--%), Beat estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueExceed expectations

0.01B--

+0.00B--%

EBITMiss expectations

-0.07B--

-0.00B--%

EPSExceed expectations

-0.52--

-0.53--

+0.0100--%

Upcoming earnings report - Q3 FY2026

Available dateNov 6, 2026

Estimate Revenue$7.75 M

Estimate EBIT-$75.39 M

Estimate EPS-$0.5875

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly